Hemab Therapeutics Holdings Inc. share price logo

Hemab Therapeutics Holdings Inc.

NASDAQ: COAG

Small Cap

$29.24

+2.79

(+10.55%)

as on

Hemab Therapeutics Holdings Inc. Stock Performance

as on June 19, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $27.61
    $29.47
    downward going graph

    5.57%

    Downside

    0.79%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    downward going graph

    100.00%

    Downside

    -100.00%

    Upside

    downward going graph

Hemab Therapeutics Holdings Inc. share price movements today

Previous Close
$26.45
Open
$28.18
Volume
379.2K
Day's Low - High
$27.61 - $29.47

Hemab Therapeutics Holdings Inc. Historical Returns

1 Month Return
+ 14.94 %
3 Month Return
0 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Hemab Therapeutics Holdings Inc. Stock Fundamentals & Key Indicators

Check Hemab Therapeutics Holdings Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.3B

EPS (TTM)

-3.035

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

-46.99%

Hemab Therapeutics Holdings Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Hemab Therapeutics Holdings Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
NA$1.3BNANA0.00%NA
BUY$37.7B57.21%71.2112.55%NA
BUY$116.5B140.42%27.2235.51%NA
BUY$63.7B13.39%14.8529.65%0.58%

Indian Investors' Interest in Hemab Therapeutics Holdings Inc. Stock

Search interest for Hemab Therapeutics Holdings Inc. Stock has increased by 100% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:100% versus previous 30 day period

Hemab Therapeutics Holdings Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2025
Mar 2026
Total Revenue
-
-
Gross Profit
-
-
Operating Income
-16
-23
EBITDA
-
-
Interest Expense
-
-
Depreciation
0
0
Income Before Tax
-15
-22
Income Tax Expense
-
-
Net Income
-15
-22
Net Profit Margin
0.00%
0.00%

Hemab Therapeutics Holdings Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2024
Dec 2025
Total Revenue
-
-
Gross Profit
-
-
Operating Income
-50
-70
EBITDA
-
-
Interest Expense
-
-
Depreciation
0
0
Income Before Tax
-48
-64
Income Tax Expense
-
-
Net Income
-48
-63
Net Profit Margin
0.00%
0.00%

Hemab Therapeutics Holdings Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2026
Net Income
-22
Operating Cash Flow
-21
Investing Cash Flow
-
Financing Cash Flow
0
Change in Cash
-38

Hemab Therapeutics Holdings Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2025
Net Income
-63
Operating Cash Flow
-61
Investing Cash Flow
-
Financing Cash Flow
156
Change in Cash
13

Hemab Therapeutics Holdings Inc. News & Key Events

  • img

    Today's Timeline - 26 May

    Tue, 07:38 PM

    -

    Goldman Sachs initiates coverage of Hemab Therapeutics with a Buy rating and $36 price target, citing strong upside potential.

Insights on Hemab Therapeutics Holdings Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, COAG stock has moved up by 17.1%

About Hemab Therapeutics Holdings Inc.

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
OrganisationHemab Therapeutics Holdings Inc.
Headquarters101 Main Street, Cambridge, MA, United States, 02142
IndustryBiotechnology
CEODr. Benny Sorensen M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Hemab Therapeutics Holdings Inc.

Name

Title

Ms. Cecile Bonvoisin M.Sc.

Senior Vice President of CMC & Manufacturing

Ms. Tara O'Meara

Senior Vice President of Development Operations

Dr. Benny Sorensen M.D., Ph.D.

President, CEO & Director

Mr. Mads Nikolaj Behrndt-Eriksen M.Sc.

CFO & GM

Dr. Catherine Eilleen Madigan M.D.

Chief Medical Officer

Dr. Ananthram Sreenivasa Murthy M.Sc., Ph.D.

Chief Operating Officer

FAQs

What is Hemab Therapeutics Holdings Inc. share price today?

Hemab Therapeutics Holdings Inc. share price today is $29.24 as on at the close of the market. Hemab Therapeutics Holdings Inc. share today touched a day high of $29.47 and a low of $27.61.

What is the 52 week high and 52 week low for Hemab Therapeutics Holdings Inc. share?

Hemab Therapeutics Holdings Inc. share touched a 52 week high of $0 on and a 52 week low of $0 on . Hemab Therapeutics Holdings Inc. stock price today i.e. is closed at $29.24,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Hemab Therapeutics Holdings Inc.'s market capitalisation today?

Hemab Therapeutics Holdings Inc. market capitalisation is $0.00T as on .

How to invest in Hemab Therapeutics Holdings Inc. Stock (COAG) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Hemab Therapeutics Holdings Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Hemab Therapeutics Holdings Inc. Shares that will get you 0.0513 shares as per Hemab Therapeutics Holdings Inc. share price of $29.24 per share as on June 19, 2026 at 8:45 am IST.

What is the minimum amount required to buy Hemab Therapeutics Holdings Inc. Stock (COAG) from India?

Indian investors can start investing in Hemab Therapeutics Holdings Inc. (COAG) shares with as little as ₹94.31 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in Hemab Therapeutics Holdings Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Hemab Therapeutics Holdings Inc. share’s latest price of $29.24 as on June 19, 2026 at 8:45 am IST, you will get 0.3420 shares of Hemab Therapeutics Holdings Inc.. Learn more about fractional shares .